Validity Of Cost-effectiveness Models Based On Randomized Clinical Trials

Cost-effectiveness studies are widely used to guide prescribing policy in many countries, as part of health technology assessment programmes. However, a new study published this week in /PLoS// Medicine/ by Tjeerd-Pieter van Staa and colleagues suggests that cost-effectiveness analyses based on data from randomized controlled trials may not be realistic enough to accurately inform policy…

Go to Source

People who read this also read

• ACP Addresses Role Of Evidence Based Medicine In Clinical Decision-Making
  The controversy over recent breast cancer screening guidelines offers an opportunity to engage individual patients in an informed discussion of the importance of evidence-based clinical efficacy assessments in contributing to better care decisions, Donna Sweet, MD, MACP told the Subcommittee on Heal...
• Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial
  Prospectively collected resource utilization and health utility data for patients with CRC in the CO.17 study who received best supportive care +/- cetuximab were assessed for cost effectiveness. Journal of the National Cancer Institute (Source: Medscape Hematology-Oncology Headlines) Go to SourceR...
• Endocyte Officials To Present Results From Four Clinical Trials At ASCO Annual Meeting
  Endocyte Inc., a clinical-stage company developing small-molecule guided drug technologies, announces that data from four clinical studies of the company's investigational compounds will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held June 4-8 ...
• Repros Receives Guidance From FDA Regarding Clinical Hold Status Of Proellex(R)
  Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that a teleconference was held with the FDA to review the clinical hold status of Proellex®. Previously clinical studies were stopped due to findings of changes in liver enzymes at higher doses of the oral drug resulting in serious adverse eve...
• Biocancell Receives U.S. FDA Approval To Continue Phase IIb Superficial Bladder Cancer Clinical Trial And Interim Results
  Tikcro Technologies Ltd. (OTC BB: TIKRF) announced that BioCancell Therapeutics, Inc. ("Biocancell"), concluded the first 18 patient group treated pursuant to a Phase IIb clinical trial of the drug candidate BC-819 for use in superficial bladder cancer. These patients had not responded to convention...